Alton will remain with Gilead until 4 October and plans to be on hand as an advisor until the end of the year as others take ...
Gilead Sciences Inc. has named industry veteran Daniel O’Day to take the helm and help the drug company revive sales and recover from a disappointing deal. Mr. O’Day, whose hiring was announced early ...
After Roche lost its top pharma executive Dan O’Day to Gilead Sciences, the cancer giant tapped Genentech head Bill Anderson for the post, leaving a gap at the top of its crucial unit. Now, Genentech ...
Roche sales have fallen lately. The company's total annual revenue for the year is predicted to be $21.7 billion. On health IT academic estimates that 70% of medical records have incorrect information ...
Gilead Sciences has named Daniel O'Day — a longtime Roche Holdings executive — as its new CEO, according to The Wall Street Journal. Mr. O'Day will succeed John Milligan, who unexpectedly announced he ...
(Reuters) - Drugmaker Gilead Sciences Inc on Monday named Roche Holding AG’s Daniel O’Day as its new chief executive, tapping an industry veteran to fill a management vacuum. O’Day, now head of ...
Daniel O’Day, a veteran executive from Swiss pharma giant Roche, has been tapped for one of the top jobs in biotech. He’s been named the CEO of Gilead Sciences (NASDAQ: GILD), which is searching for a ...
REUTERS/Ruben Sprich/File Photo REUTERS: Drugmaker Gilead Sciences Inc on Monday named Roche Holding AG's Daniel O'Day as its new chief executive, tapping an industry veteran to fill a management ...